TOXOSTAT— 510(k) K944867

Name: FDA 510(k) clearance K944867
Creator: U.S. Food and Drug Administration
Published: 1996-05-14

Substantially Equivalent

Bio-Whittaker, Inc., A Cambrex Co.

FDA 510(k) clearance K944867 for TOXOSTAT, Substantially Equivalent on 1996-05-14. Applicant: Bio-Whittaker, Inc., A Cambrex Co.. Device class: 2.

Clearance details

Applicant: Bio-Whittaker, Inc., A Cambrex Co.
Product code: Code LGD
Device class: Class 2
Regulation: 21 CFR 866.3780
Advisory panel: Microbiology
Date received: 1994-09-27
Decision date: 1996-05-14
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Walkersville, MD, US

Download summary PDF View on FDA.gov ↗

Recent devices under product code LGD

view all

K242022 — Access Toxo IgG2025-03-28
K242095 — Access Toxo IgM II2024-10-11
K233932 — Alinity i Toxo IgM2024-08-30
K210596 — ARCHITECT Toxo IgG2022-05-19
K162678 — Elecsys Toxo IgM, Elecsys Toxo IgM PreciControl2017-06-23

More clearances from Bio-Whittaker, Inc., A Cambrex Co.

view all

K971508 — RHMK II CELL CULTURE, AN EXPANDED PRIMARY RHESUS MONKEY KIDNEY CELL CULTURE1997-09-17
K950227 — RUBELISA (RUBESTAT)1995-08-15

Adverse events under product code LGD

product code LGD

Malfunction: 502
Total: 502

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.